THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference taking ...
Infecteds” and rogue punks go bonkers in director Nia DaCosta’s twisted, more brutal and freakishly funny continuation.
Lexicon Pharmaceuticals, Inc. is downgraded to Hold due to repeated FDA rejections of ZYNQUISTA for T1D and catalysts. Read more on LXRX stock here.
The Lexicon family of companies provides services including construction management, steel fabrication, erection, mechanical ...
Our End-of-Phase 2 meeting with FDA was productive and provided Lexicon with the insights needed to design a robust Phase 3 program, with the goal of making the first non-opioid DPNP medicine ...
Leatherman Revamped Its Iconic Wave, and the Result Will Help You Get Off the Fence About Multitools
I get it. There’s a seemingly endless number of multitools to buy. From well established brands I love, it’s hard to make a bad choice among the dozens of options with that balance of useful tools and ...
No such conversion happened in the series finale of the hit Netflix show “Stranger Things,” which was released on New Year’s ...
We recently published a list of the 12 Best Investment Websites To Research Stocks. In this article, we will look at where ...
Lexicon Pharmaceuticals Inc. announced that it received no objections from the U.S. FDA to move pilavapadin, its non-opioid candidate for diabetic peripheral neuropathic pain, into phase III study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results